newsfilter
← Latest News
Business Wire·

Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against Gedatolisib

In two preclinical breast cancer xenograft models (abstract #431P), PIKTOR inhibited tumor growth to a comparable or greater extent than intravenous gedatolisibPIKTOR inhibited HR+/HER2- breast cancer xenograft tumor